CD4 and cervical cancer: An early start to ART, as recommended by the World Health Organization (WHO) in 2012 and by the HMB since 2013[47,48], may change this scenario, since starting treatment with a high CD4+ T lymphocyte count and no other significant alterations to the immune system may contribute to HR-HPV clearance, as well as a reduction in HSIL and cervix cancer incidence, therefore providing better outcomes for WLHA.